Abstract
At the request of the German Federal Institute for Drugs and Medical Devices (BfArM), the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review procedure regarding the basic evaluation of the benefit-risk balance of solutions for infusion containing hydroxyethyl starch (HES). Here we present an overview of facts to provide emergency physicians objective information.
Owner only: item control page
Altmetric
Altmetric